Bulevirtide shows promising results in the treatment of chronic hepatitis D. In a phase 3 trial, 150 patients with chronic HDV were evaluated for the safety and efficacy of bulevirtide monotherapy. Bulevirtide was found to be safe and raised the proportion of patients with undetectable hepatitis D virus RNA in the research. At week 48, the primary objective was a combined response of undetectable HDV RNA or a level that dropped by at least 2 log10 IU/mL and alanine transaminase. When compared to the control group, a considerably higher percentage of patients in the bulevirtide groups exhibited a virologic and biochemical response. Specifically, 45% of patients in the 2 mg group and 48% in the 4 mg group.

To know more: About the original article click here.